Our research and development strategy is to continue to invest in innovative methods, which are essential to the long-term success of health care products, with an emphasis on biotechnology research.
Liptis Research organizes the efforts of our employees worldwide in the search for and development of new drugs that will enhance both the quality of health care and the products Liptis offers.
Our commitment to research and development demonstrates our focus on solving human health problems. Our goal is to consistently produce new and innovative treatments that provide the world with better therapies.
Liptis's musculoskeletal research developed an important new therapies for patients with joint and bone disorders. Our products include treatments for osteoarthritis that help patients lead more active lives with less pain. In addition, Liptis has a strong presence in the treatment of osteoarthritis, our product Dorofen is one of the best sellers in its category. Liptis scientists are investigating novel treatments for bone and tissue repair, which may impact fracture healing and post-surgical recovery.
Our broad and expanding internal medicine franchise includes cardiovascular and gastrointestinal products. Liptis internal medicine researchers are exploring novel approaches to treat diabetes with our products Glybufen, Diofen, and Glucostat, treat depression with Modostat, treat vascular disorders with Cepress and treat liver diseases with Hepachol.
Liptis has a long history of pioneering developments in pharmaceuticals with leading products in the areas of women's health care, musculoskeletal disorder and cardiovascular therapy.
